ATE282330T1 - Ernährungszusammensetzung, die einen vorläufer von anandamide enthält - Google Patents

Ernährungszusammensetzung, die einen vorläufer von anandamide enthält

Info

Publication number
ATE282330T1
ATE282330T1 AT00964172T AT00964172T ATE282330T1 AT E282330 T1 ATE282330 T1 AT E282330T1 AT 00964172 T AT00964172 T AT 00964172T AT 00964172 T AT00964172 T AT 00964172T AT E282330 T1 ATE282330 T1 AT E282330T1
Authority
AT
Austria
Prior art keywords
composition
anandamide
precursor
nutritional composition
composition containing
Prior art date
Application number
AT00964172T
Other languages
English (en)
Inventor
Alvin Berger
Gayle Crozier
Original Assignee
Nestle Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10862297&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE282330(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nestle Sa filed Critical Nestle Sa
Application granted granted Critical
Publication of ATE282330T1 publication Critical patent/ATE282330T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
AT00964172T 1999-10-07 2000-09-14 Ernährungszusammensetzung, die einen vorläufer von anandamide enthält ATE282330T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9923738.0A GB9923738D0 (en) 1999-10-07 1999-10-07 Nutritional composition
PCT/EP2000/008995 WO2001024645A1 (en) 1999-10-07 2000-09-14 Nutritional composition

Publications (1)

Publication Number Publication Date
ATE282330T1 true ATE282330T1 (de) 2004-12-15

Family

ID=10862297

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00964172T ATE282330T1 (de) 1999-10-07 2000-09-14 Ernährungszusammensetzung, die einen vorläufer von anandamide enthält

Country Status (10)

Country Link
US (1) US8323680B1 (de)
EP (1) EP1221867B2 (de)
AT (1) ATE282330T1 (de)
AU (1) AU7518700A (de)
CA (1) CA2386362C (de)
DE (1) DE60016007T3 (de)
ES (1) ES2234665T5 (de)
GB (1) GB9923738D0 (de)
PT (1) PT1221867E (de)
WO (1) WO2001024645A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030087657A (ko) 2001-03-27 2003-11-14 더 리전츠 오브 더 유니버시티 오브 캘리포니아 체지방 감소 및 지방산 대사 조절을 위한 방법, 화합물 및조성물
AU2002354901A1 (en) * 2001-07-16 2003-03-03 Edward Hogestatt Compounds with analgesic, antipyretic and/or anti-inflammatory activity
DE60228713D1 (de) * 2001-07-18 2008-10-16 Unilever Nv Zusammensetzungen für die behandlung von haaren und/oder kopfhaut
JP2003048831A (ja) 2001-08-02 2003-02-21 Suntory Ltd 脳機能の低下に起因する症状あるいは疾患の予防又は改善作用を有する組成物
TW200407110A (en) * 2001-11-23 2004-05-16 Astrazeneca Ab New use for the treatment of gastroesophageal reflux disease
GB0311081D0 (en) 2003-05-14 2003-06-18 Btg Internat Limted Treatment of neurodegenerative conditions
EP2324828A1 (de) 2003-08-18 2011-05-25 BTG International Limited Behandlung neurodegenerativer Erkrankungen
JP2007509066A (ja) * 2003-10-16 2007-04-12 ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア 体脂肪を減らし、食欲を抑制し、脂肪酸代謝を調節するための食物および他の組成物、化合物ならびに方法
JP4993852B2 (ja) 2004-09-17 2012-08-08 サントリーホールディングス株式会社 ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物
GB0504362D0 (en) 2005-03-02 2005-04-06 Btg Int Ltd Cytokine modulators
JP5967855B2 (ja) 2005-06-30 2016-08-10 サントリーホールディングス株式会社 日中活動量の低下および／又はうつ症状の改善作用を有する組成物
KR101578498B1 (ko) 2006-12-28 2015-12-18 산토리 홀딩스 가부시키가이샤 신경 재생제
WO2009124551A2 (en) * 2008-04-09 2009-10-15 Neurokey A/S Use of hypothermia inducing drugs
WO2009124553A2 (en) * 2008-04-09 2009-10-15 Neurokey A/S Use of hypothermia inducing drugs
EP2744488A4 (de) * 2011-08-15 2014-07-09 Nestec Sa Verfahren zur linderung von stressbedingten symptomen oder zuständen
ITMI20130354A1 (it) 2013-03-08 2014-09-09 Again Life Italia Srl Miscela di acidi grassi (f.a.g. fatty acids group) per uso nel trattamento di patologie infiammatorie.
WO2016020828A1 (en) * 2014-08-08 2016-02-11 Raffaele Migliaccio Mixture of fatty acids and palmitoylethanolamide for use in the treatment of inflammatory and allergic pathologies
ITUB20153066A1 (it) 2015-08-11 2017-02-11 Graal S R L Composizione alimentare e/o nutraceutica contenente pea
SG10201802129QA (en) 2017-07-05 2019-02-27 Frimline Private Ltd A pharmaceutical composition for neuropathic pain
PH12018000227B1 (en) 2017-09-05 2019-03-11 Frimline Private Ltd A pharmaceutical composition for improving or preventing progression of chronic kidney disease
WO2024124172A1 (en) * 2022-12-09 2024-06-13 The Trustees Of The University Of Pennsylvania Compositions and methods for stimulating and/or enhancing exercise motivation and/or physical performance

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8916734D0 (en) * 1989-07-21 1989-09-06 Efamol Holdings Pharmaceutical and dietary uses of fatty acids
GB9026648D0 (en) * 1990-12-07 1991-01-23 Efamol Holdings Nutrition
WO1993020717A2 (en) * 1992-04-13 1993-10-28 Research Corporation Technologies, Inc. Reducing gastrointestinal irritation in infant nutrition
GB9224809D0 (en) * 1992-11-26 1993-01-13 Scotia Holdings Plc Schizophrenia
US5618955A (en) * 1992-11-30 1997-04-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Fatty acid derivatives and pharmaceutical compositions containing same
IL103932A (en) 1992-11-30 1997-02-18 Yissum Res & Dev Fatty acid and pharmaceutical compositions containing them
EP2140863A1 (de) * 1993-06-09 2010-01-06 Martek Biosciences Corporation Verwendung von Docosahexaensäure zur Herstellung eines Arzneimittels zur Behandlung von neurologischen Störungen
GB9510636D0 (en) * 1995-05-25 1995-07-19 Scotia Holdings Plc Fatty acid treatment
WO1996040106A2 (en) 1995-06-07 1996-12-19 Martek Biosciences Corporation Methods for controlling highly unsaturated fatty acid content in various tissues
US5688825A (en) * 1996-05-31 1997-11-18 University Of Connecticut Anandamide amidase inhibitors as analgesic agents
RS49982B (sr) * 1997-09-17 2008-09-29 Euro-Celtique S.A., Sinergistička analgetička kombinacija analgetičkog opijata i inhibitora ciklooksigenaze-2
EP1558591B1 (de) * 2002-10-07 2014-05-07 The Regents of The University of California Modulation von angstzuständen durch blockade der anandamidhydrolyse

Also Published As

Publication number Publication date
DE60016007T3 (de) 2009-07-09
ES2234665T3 (es) 2005-07-01
WO2001024645A1 (en) 2001-04-12
DE60016007T2 (de) 2006-03-02
AU7518700A (en) 2001-05-10
CA2386362A1 (en) 2001-04-12
EP1221867B1 (de) 2004-11-17
GB9923738D0 (en) 1999-12-08
EP1221867B2 (de) 2008-08-20
ES2234665T5 (es) 2009-03-01
DE60016007D1 (de) 2004-12-23
CA2386362C (en) 2012-08-14
PT1221867E (pt) 2005-04-29
US8323680B1 (en) 2012-12-04
EP1221867A1 (de) 2002-07-17

Similar Documents

Publication Publication Date Title
DE60016007D1 (de) Ernährungszusammensetzung, die einen vorläufer von anandamide enthält
PL364174A1 (en) Fibrate-statin combinations with reduced fed-fasted effects
US11471432B2 (en) Supporting immunomodulatory agent
MX2007006707A (es) Acidos grasos omega-3 y agente dislipidemico para terapia lipidica.
IL112518A0 (en) Thyroid hormone fast dispersing pharmaceutical composition
WO2004001383A3 (en) Safe and effective nutritional supplement formulatins and associated regimens adapted to prevent and/or treat targeted diseases or medical or health conditions, and related methods
EA200300046A1 (ru) Быстро увеличивающаяся в объеме композиция для удерживания и контролированного выделения терапевтических агентов в желудке и лекарственные формы, включающие композицию
WO2007012019A3 (en) Medicaments containing famotidine and ibuprofen and administration of same
ATE298324T1 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
RU95101385A (ru) Продукты, содержащие g-csf и tnf связующие протеина
SE8105561L (sv) Anvendning av pyridoxin-alfa-ketoglutarat vid profylax av hypermjolksyraemi
BR9809694A (pt) Processo e composição para administração de taxanos oralmente a pacientes humanos
BR0015149A (pt) Método e composições para administração de taxanos oralmente a pacientes humanos
BR0011447A (pt) Composição compreendendo esfingomielinase alcalina para aplicação como uma preparação dietética, suplemento alimentar ou produto farmacêutico
MX2022012693A (es) Composicion que comprende metilfolato.
SI1596841T1 (sl) Terapevtski sistem amoksicilina in klavulanske kisline
BR0116653A (pt) Medicamento contendo uma poliamina como substância ativa
WO2014176417A1 (en) Topical preparation for bypassing gi tract, delivery of therapeutics, and trans-epithelial drug delivery system
EP1550443A4 (de) Zusammensetzung gegen stressbedingte erkrankungen
CA2429793A1 (en) Interferon therapeutic effect enhancer
ATE267162T1 (de) Therapeutisch und/oder ernährungsphysiologisch verbesserte derivate aktiver inhaltsstoffe und oral verabreichbare zusammensetzungen, die diese enthalten
GB2286528A (en) Dietary supplement
KR960700701A (ko) 파라세타몰 및 l-시스테인 또는 이것의 전구물질을 함유하는 약제조성물(pharmaceutical compositions comprising paracetamol and l-cysteine or a precursor thereof)
CA2474703A1 (en) Therapeutic agent of glaucoma comprising bunazosin and prostaglandins
IL164317A0 (en) Statin therapy for enhancing cognitive maintenance

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1221867

Country of ref document: EP

UEP Publication of translation of european patent specification

Ref document number: 1221867

Country of ref document: EP